Wound Complications in Head and Neck Surgery

CompletedOBSERVATIONAL
Enrollment

51

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

April 1, 2020

Study Completion Date

May 1, 2020

Conditions
Hypothyroidism; SurgeryHead and Neck CancerWound HealLaryngeal CancerLaryngeal Fistula
Interventions
DRUG

Levothyroxine

Immediately post-operatively, all patients undergoing laryngectomy will be started on established weight-based dosing of levothyroxine administered intravenously due to the variable enteral absorption in post-operative patients including those on continuous tube feed regimens. Standard enteral dose is 1.6 mcg/kg/day. Eighty percent of this dose (1.3 mcg/kg/day) will be given IV to account for the increased bioavailability of IV levothyroxine compared to enteral levothyroxine. The maximum dose will be 200 mcg/day. Patients previously on levothyroxine at doses lower than the above dose will changed to the aforementioned standard dose. Patients on higher doses of levothyroxine pre-operatively will be maintained on on their current dosing.

Trial Locations (1)

48019

University of Michigan, Ann Arbor

All Listed Sponsors
lead

University of Michigan

OTHER

NCT03134976 - Wound Complications in Head and Neck Surgery | Biotech Hunter | Biotech Hunter